SKYEY Skyepharma Plc featured news, full reports, and detailed charts
Skyepharma Plc (SKYEY/SKYEY.PK) Wrap Up:
SkyePharma PLC engages in the research, development, manufacture, and sale of prescription pharmaceutical products. It offers inhalation products, which include Pulmicort, a hydrofluoroalkane metered dose inhaler; and Foradil Certihaler, a multi-dose dry powder inhaler device. The company also provides oral products, such as Sular, a calcium channel blocker antihypertensive therapy; Triglide for lipid disorders; Paxil CR, a selective serotonin reuptake inhibitor antidepressant; Xatral OD, a selective alpha-blocker for treating the urinary symptoms of benign prostatic hyperplasia; and Coruno for the oral treatment of chronic angina pectoris. In addition, its oral products include Madopar DR for the oral treatment of various forms of the Parkinson disease; diclofenac-ratiopharm uno, a dual release diclofenac sodium formulation; ZYFLO CR, a leukotriene synthesis inhibitor oral anti-inflammatory asthma drug; and Requip XL, a once daily formulation for Parkinson?s disease. Further, the company provides Solaraze, a hyaluronic acid gel for actinic keratosis. Its pipeline products also include Flutiform HFA-MDI, a fixed-dose combination of formoterol and the inhaled steroid fluticasone in a metered dose inhaler; Lodotra, a Phase III trial product, a modified-release formulation of prednisone/an anti-inflammatory drug for treating the pain and stiffness caused by rheumatoid arthritis; and SKP-1041, a Phase I trial product for sleep maintenance. The company has partnerships with GlaxoSmithKline, Sanofi-Aventis, Roche, Therabel, ratiopharm, Cornerstone Therapeutics, Inc, Sciele Pharma Inc, AstraZeneca, Abbott Respiratory LLC, Mundipharma International Corporation Limited, Somnus Therapeutics Inc, Nitec Pharma AG, and Kyorin Pharmaceutical Company Ltd. SkyePharma PLC was founded in 1910 and is headquartered in London, the United Kingdom.SkyePharma PLC (SKYEY:OTC)
|
Market Cap
3.8B
|
Total Revenue
50.3M
|
|
|
EBITDA
1.1M
|
DILUTED EPS TTM
-2.11
|
|
|
P/E
--
|
P/S
35.9x
|
|
|
Return On Asset
-3.63
|
Return On Equity
26.45
|
|
| K = Thousands M = Millions B = Billions | ||
SKYEY Top Compensated Officers
Executives, Board Directors
Key developments for SkyePharma PLC (SKYEY)
SkyePharma plc announced that its Chairman, Jeremy Scudamore, has informed the Board that he intends to step down from the Board at the end of 2009 for health reasons. Frank Condella, Non-Executive Director and former CEO of SkyePharma, has agreed to take over as Non-Executive Chairman with effect from 1 January 2010.
SkyePharma plc announced that its development and marketing partner Mundipharma International Corporation Limited has successfully completed the final Phase III clinical study for the European development programme for FlutiformTM, with the higher dose strength study (FLT 3503) meeting its primary endpoints. This will enable the regulatory filing with the European authorities to take place in first quarter 2010 as planned. Study FLT-3503 included 529 patients, who met the requirements for the 'per protocol' analysis, and were suffering from severe, persistent and reversible asthma. They were treated in an eight week double-blind, double dummy, randomised multiple centre four arm parallel group study to assess the efficacy and safety of FlutiformTM. The four treatment arms were: (1) FlutiformTM (fluticasone 500 microgram/formoterol 20 microgram); (2) Flixotide (fluticasone 500 microgram) and Foradil (formoterol 24 microgram)administered concurrently; (3) FlutiformTM (fluticasone 100 microgram /formoterol 10 microgram); and (4) Flixotide (fluticasone 500 microgram). Enrolled patients had to have a disease history of at least six months. The changes in the mean pre-dose FEV1 (Forced Expiratory Volume in the first second) at baseline to the pre-dose FEV1 and the two hour post-dose FEV1 at eight weeks, were the primary endpoints measured and the top line analysis confirms that FlutiformTM produces similar results (statistically not inferior) when compared with the concurrent administration of Flixotide and Foradil. The results demonstrated that FlutiformTM was well tolerated in the study patients. The analysis of multiple secondary endpoints is ongoing.
SkyePharma plc expected to Report Fiscal Year 2010 Results on March 25, 2010. This event was calculated by Capital IQ (Created on October 30, 2009).
SKYEY Competitors
| Company | Last | Change |
| Depomed Inc | $3.30 USD | +0.03 |
| Nektar Therapeutics | $8.64 USD | -0.09 |
| QLT Inc | C$3.91 CAD | -0.04 |
| Vernalis | 84.00 GBX | -1.00 |
| XenoPort Inc | $16.35 USD | +0.09 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | SKYEY | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 35.9x |
|
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 34.6x |
|
|
SKYEY |
||
SKYEY transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||